Search

Your search keyword '"Bouvier N"' showing total 205 results
Start Over Author "Bouvier N"
205 results on '"Bouvier N"'

1. COVID-19 et transplantation d’organes, les leçons du recensement national de la Société francophone de transplantation

Author

Caillard, S., Moulin, B., Fafi-Kremer, S., Hazzan, M., Anglicheau, D., Hertig, A., Tourret, J., Barrou, B., Morelon, E., Thaunat, O., Couzi, L., Merville, P., Moal, V., Legris, T., Westeel, P.-F., Jaureguy, M., Frimat, L., Ducloux, D., Bamoulid, J., Bertrand, D., Tsimaratos, M., Garaix-Gilardo, F., Dumortier, J., Mussot, S., Roux, A., Sebbag, L., Le Meur, Y., Blancho, G., Masset, C., Kamar, N., Francois, H., Rondeau, E., Bouvier, N., Mousson, C., Buchler, M., Gatault, P., Augusto, J.-F., Duveau, A., Vigneau, C., Morin, M.-C., Chemouny, J., Golbin, L., Grimbert, P., Matignon, M., Durrbach, A., Greze, C., Snanoudj, R., Colosio, C., Schvartz, B., Malvezzi, P., Mariat, C., Thierry, A., Le Quintrec, M., Sicard, A., Rerolle, J.P., Heng, A.-É., Garrouste, C., Coponat, H.V., Epailly, É., Brugiere, O., Dharancy, S., Salame, É., Saliba, F., and Caillard, Sophie

Published
2022
Full Text
View/download PDF

2. Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers

Author

Shukla, N., Levine, M. F., Gundem, G., Domenico, D., Spitzer, B., Bouvier, N., Arango-Ossa, J. E., Glodzik, D., Medina-Martínez, J. S., Bhanot, U., Gutiérrez-Abril, J., Zhou, Y., Fiala, E., Stockfisch, E., Li, S., Rodriguez-Sanchez, M. I., O’Donohue, T., Cobbs, C., Roehrl, M. H. A., Benhamida, J., Iglesias Cardenas, F., Ortiz, M., Kinnaman, M., Roberts, S., Ladanyi, M., Modak, S., Farouk-Sait, S., Slotkin, E., Karajannis, M. A., Dela Cruz, F., Glade Bender, J., Zehir, A., Viale, A., Walsh, M. F., Kung, A. L., and Papaemmanuil, E.

Published
2022
Full Text
View/download PDF

3. Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma

Author

Kinnaman, M, Zaccaria, S, Makohon-Moore, A, Arnold, B, Levine, M, Gundem, G, Arango Ossa, J, Glodzik, D, Rodriguez-Sanchez, M, Bouvier, N, Li, S, Stockfisch, E, Dunigan, M, Cobbs, C, Bhanot, U, You, D, Mullen, K, Melchor, J, Ortiz, M, O'Donohue, T, Slotkin, E, Wexler, L, Dela Cruz, F, Hameed, M, Glade Bender, J, Tap, W, Meyers, P, Papaemmanuil, E, Kung, A, Iacobuzio-Donahue, C, Kinnaman M. D., Zaccaria S., Makohon-Moore A., Arnold B., Levine M. F., Gundem G., Arango Ossa J. E., Glodzik D., Rodriguez-Sanchez M. I., Bouvier N., Li S., Stockfisch E., Dunigan M., Cobbs C., Bhanot U. K., You D., Mullen K., Melchor J. P., Ortiz M. V., O'Donohue T. J., Slotkin E. K., Wexler L. H., Dela Cruz F. S., Hameed M. R., Glade Bender J. L., Tap W. D., Meyers P. A., Papaemmanuil E., Kung A. L., Iacobuzio-Donahue C. A., Kinnaman, M, Zaccaria, S, Makohon-Moore, A, Arnold, B, Levine, M, Gundem, G, Arango Ossa, J, Glodzik, D, Rodriguez-Sanchez, M, Bouvier, N, Li, S, Stockfisch, E, Dunigan, M, Cobbs, C, Bhanot, U, You, D, Mullen, K, Melchor, J, Ortiz, M, O'Donohue, T, Slotkin, E, Wexler, L, Dela Cruz, F, Hameed, M, Glade Bender, J, Tap, W, Meyers, P, Papaemmanuil, E, Kung, A, Iacobuzio-Donahue, C, Kinnaman M. D., Zaccaria S., Makohon-Moore A., Arnold B., Levine M. F., Gundem G., Arango Ossa J. E., Glodzik D., Rodriguez-Sanchez M. I., Bouvier N., Li S., Stockfisch E., Dunigan M., Cobbs C., Bhanot U. K., You D., Mullen K., Melchor J. P., Ortiz M. V., O'Donohue T. J., Slotkin E. K., Wexler L. H., Dela Cruz F. S., Hameed M. R., Glade Bender J. L., Tap W. D., Meyers P. A., Papaemmanuil E., Kung A. L., and Iacobuzio-Donahue C. A.

Abstract

Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a metastatic or relapse site. Subclonal copy-number alterations were identified in all patients except one. In 5 patients, subclones from the primary tumor emerged and dominated at subsequent relapses. MYC gain/amplification was enriched in the treatment-resistant clones in 6 of 7 patients with multiple clones. Amplifications in other potential driver genes, such as CCNE1, RAD21, VEGFA, and IGF1R, were also observed in the resistant copy-number clones. A chromosomal duplication timing analysis revealed that complex genomic rearrangements typically occurred prior to diagnosis, supporting a macroevolutionary model of evolution, where a large number of genomic aberrations are acquired over a short period of time followed by clonal selection, as opposed to ongoing evolution. A mutational signature analysis of recurrent tumors revealed that homologous repair deficiency (HRD)-related SBS3 increases at each time point in patients with recurrent disease, suggesting that HRD continues to be an active mutagenic process after diagnosis. Overall, by examining the clonal relationships between temporally and spatially separated samples from patients with relapsed/refractory osteosarcoma, this study sheds light on the intratumor heterogeneity and potential drivers of treatment resistance in this disease. Significance: The chemoresistant population in recurrent osteosarcoma is subclonal at diagnosis, emerges at the time of primary resection due to selective pressure from neoadjuvant chemotherapy, an

Published
2023

4. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study

Author

Gatault, P., Kamar, N., Büchler, M., Colosio, C., Bertrand, D., Durrbach, A., Albano, L., Rivalan, J., Le Meur, Y., Essig, M., Bouvier, N., Legendre, C., Moulin, B., Heng, A.-E., Weestel, P.-F., Sayegh, J., Charpentier, B., Rostaing, L., Thervet, E., and Lebranchu, Y.

Published
2017
Full Text
View/download PDF

10. PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

Author

Alhalabi, K.T. Stichel, D. Sievers, P. Peterziel, H. Sommerkamp, A.C. Sturm, D. Wittmann, A. Sill, M. Jäger, N. Beck, P. Pajtler, K.W. Snuderl, M. Jour, G. Delorenzo, M. Martin, A.M. Levy, A. Dalvi, N. Hansford, J.R. Gottardo, N.G. Uro-Coste, E. Maurage, C.-A. Godfraind, C. Vandenbos, F. Pietsch, T. Kramm, C. Filippidou, M. Kattamis, A. Jones, C. Øra, I. Mikkelsen, T.S. Zapotocky, M. Sumerauer, D. Scheie, D. McCabe, M. Wesseling, P. Tops, B.B.J. Kranendonk, M.E.G. Karajannis, M.A. Bouvier, N. Papaemmanuil, E. Dohmen, H. Acker, T. von Hoff, K. Schmid, S. Miele, E. Filipski, K. Kitanovski, L. Krskova, L. Gojo, J. Haberler, C. Alvaro, F. Ecker, J. Selt, F. Milde, T. Witt, O. Oehme, I. Kool, M. von Deimling, A. Korshunov, A. Pfister, S.M. Sahm, F. Jones, D.T.W.

Abstract

Large-scale molecular profiling studies in recent years have shown that central nervous system (CNS) tumors display a much greater heterogeneity in terms of molecularly distinct entities, cellular origins and genetic drivers than anticipated from histological assessment. DNA methylation profiling has emerged as a useful tool for robust tumor classification, providing new insights into these heterogeneous molecular classes. This is particularly true for rare CNS tumors with a broad morphological spectrum, which are not possible to assign as separate entities based on histological similarity alone. Here, we describe a molecularly distinct subset of predominantly pediatric CNS neoplasms (n = 60) that harbor PATZ1 fusions. The original histological diagnoses of these tumors covered a wide spectrum of tumor types and malignancy grades. While the single most common diagnosis was glioblastoma (GBM), clinical data of the PATZ1-fused tumors showed a better prognosis than typical GBM, despite frequent relapses. RNA sequencing revealed recurrent MN1:PATZ1 or EWSR1:PATZ1 fusions related to (often extensive) copy number variations on chromosome 22, where PATZ1 and the two fusion partners are located. These fusions have individually been reported in a number of glial/glioneuronal tumors, as well as extracranial sarcomas. We show here that they are more common than previously acknowledged, and together define a biologically distinct CNS tumor type with high expression of neural development markers such as PAX2, GATA2 and IGF2. Drug screening performed on the MN1:PATZ1 fusion-bearing KS-1 brain tumor cell line revealed preliminary candidates for further study. In summary, PATZ1 fusions define a molecular class of histologically polyphenotypic neuroepithelial tumors, which show an intermediate prognosis under current treatment regimens. © 2021, The Author(s).

Published
2021

11. PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

Author

Alhalabi, KT, Stichel, D, Sievers, P, Peterziel, H, Sommerkamp, AC, Sturm, D, Wittmann, A, Sill, M, Jaeger, N, Beck, P, Pajtler, KW, Snuderl, M, Jour, G, Delorenzo, M, Martin, AM, Levy, A, Dalvi, N, Hansford, JR, Gottardo, NG, Uro-Coste, E, Maurage, C-A, Godfraind, C, Vandenbos, F, Pietsch, T, Kramm, C, Filippidou, M, Kattamis, A, Jones, C, Ora, I, Mikkelsen, TS, Zapotocky, M, Sumerauer, D, Scheie, D, McCabe, M, Wesseling, P, Tops, BBJ, Kranendonk, MEG, Karajannis, MA, Bouvier, N, Papaemmanuil, E, Dohmen, H, Acker, T, von Hoff, K, Schmid, S, Miele, E, Filipski, K, Kitanovski, L, Krskova, L, Gojo, J, Haberler, C, Alvaro, F, Ecker, J, Selt, F, Milde, T, Witt, O, Oehme, I, Kool, M, von Deimling, A, Korshunov, A, Pfister, SM, Sahm, F, Jones, DTW, Alhalabi, KT, Stichel, D, Sievers, P, Peterziel, H, Sommerkamp, AC, Sturm, D, Wittmann, A, Sill, M, Jaeger, N, Beck, P, Pajtler, KW, Snuderl, M, Jour, G, Delorenzo, M, Martin, AM, Levy, A, Dalvi, N, Hansford, JR, Gottardo, NG, Uro-Coste, E, Maurage, C-A, Godfraind, C, Vandenbos, F, Pietsch, T, Kramm, C, Filippidou, M, Kattamis, A, Jones, C, Ora, I, Mikkelsen, TS, Zapotocky, M, Sumerauer, D, Scheie, D, McCabe, M, Wesseling, P, Tops, BBJ, Kranendonk, MEG, Karajannis, MA, Bouvier, N, Papaemmanuil, E, Dohmen, H, Acker, T, von Hoff, K, Schmid, S, Miele, E, Filipski, K, Kitanovski, L, Krskova, L, Gojo, J, Haberler, C, Alvaro, F, Ecker, J, Selt, F, Milde, T, Witt, O, Oehme, I, Kool, M, von Deimling, A, Korshunov, A, Pfister, SM, Sahm, F, and Jones, DTW

Abstract

Large-scale molecular profiling studies in recent years have shown that central nervous system (CNS) tumors display a much greater heterogeneity in terms of molecularly distinct entities, cellular origins and genetic drivers than anticipated from histological assessment. DNA methylation profiling has emerged as a useful tool for robust tumor classification, providing new insights into these heterogeneous molecular classes. This is particularly true for rare CNS tumors with a broad morphological spectrum, which are not possible to assign as separate entities based on histological similarity alone. Here, we describe a molecularly distinct subset of predominantly pediatric CNS neoplasms (n = 60) that harbor PATZ1 fusions. The original histological diagnoses of these tumors covered a wide spectrum of tumor types and malignancy grades. While the single most common diagnosis was glioblastoma (GBM), clinical data of the PATZ1-fused tumors showed a better prognosis than typical GBM, despite frequent relapses. RNA sequencing revealed recurrent MN1:PATZ1 or EWSR1:PATZ1 fusions related to (often extensive) copy number variations on chromosome 22, where PATZ1 and the two fusion partners are located. These fusions have individually been reported in a number of glial/glioneuronal tumors, as well as extracranial sarcomas. We show here that they are more common than previously acknowledged, and together define a biologically distinct CNS tumor type with high expression of neural development markers such as PAX2, GATA2 and IGF2. Drug screening performed on the MN1:PATZ1 fusion-bearing KS-1 brain tumor cell line revealed preliminary candidates for further study. In summary, PATZ1 fusions define a molecular class of histologically polyphenotypic neuroepithelial tumors, which show an intermediate prognosis under current treatment regimens.

Published
2021

17. HER kinase inhibition in patients with HER2-and HER3-mutant cancers

Author

Hyman, DM, Piha-Paul, SA, Won, H, Rodon, J, Saura, C, Shapiro, GI, Juric, D, Quinn, DI, Moreno, V, Doger, B, Mayer, IA, Boni, V, Calvo, E, Loi, S, Lockhart, AC, Erinjeri, JP, Scaltriti, M, Ulaner, GA, Patel, J, Tang, J, Beer, H, Selcuklu, SD, Hanrahan, AJ, Bouvier, N, Melcer, M, Murali, R, Schram, AM, Smyth, LM, Jhaveri, K, Li, BT, Drilon, A, Harding, JJ, Iyer, G, Taylor, BS, Berger, MF, Cutler, RE, Xu, F, Butturini, A, Eli, LD, Mann, G, Farrell, C, Lalani, AS, Bryce, RP, Arteaga, CL, Meric-Bernstam, F, Baselga, J, Solit, DB, Hyman, DM, Piha-Paul, SA, Won, H, Rodon, J, Saura, C, Shapiro, GI, Juric, D, Quinn, DI, Moreno, V, Doger, B, Mayer, IA, Boni, V, Calvo, E, Loi, S, Lockhart, AC, Erinjeri, JP, Scaltriti, M, Ulaner, GA, Patel, J, Tang, J, Beer, H, Selcuklu, SD, Hanrahan, AJ, Bouvier, N, Melcer, M, Murali, R, Schram, AM, Smyth, LM, Jhaveri, K, Li, BT, Drilon, A, Harding, JJ, Iyer, G, Taylor, BS, Berger, MF, Cutler, RE, Xu, F, Butturini, A, Eli, LD, Mann, G, Farrell, C, Lalani, AS, Bryce, RP, Arteaga, CL, Meric-Bernstam, F, Baselga, J, and Solit, DB

Abstract

Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, 'basket' trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.

Published
2018

19. Valorisation du Calophyllum inophyllum du Pacifique Sud (Calo-PS)

Author

Raharivelomanana, Phila, Lecellier, G., Nour, M ., Hnawia, E., bouvier, N. Le, Ginigini, J., Aalbersberg, W., Rat, P., Leguillier, T., Touboul, O., Ecosystèmes Insulaires Océaniens (UMR 241) (EIO), Université de la Polynésie Française (UPF)-Institut Louis Malardé [Papeete] (ILM), Institut de Recherche pour le Développement (IRD)-Institut de Recherche pour le Développement (IRD)-Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER), Laboratoire d'Excellence CORAIL (LabEX CORAIL), Université des Antilles (UA)-Institut d'écologie et environnement-Université de la Nouvelle-Calédonie (UNC)-Université de la Polynésie Française (UPF)-Université de La Réunion (UR)-Institut Français de Recherche pour l'Exploitation de la Mer (IFREMER)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École des hautes études en sciences sociales (EHESS)-Université des Antilles et de la Guyane (UAG)-Institut de Recherche pour le Développement (IRD), Laboratoire Insulaire du Vivant et de l'Environnement (LIVE), Université de la Nouvelle-Calédonie (UNC), Equipe Avenir. University of Burgundy, Université de la Polynésie française, and Fonds-Pacifique

Subjects
Pacifique Sud, [SDV.BV]Life Sciences [q-bio]/Vegetal Biology, Calophyllum inophyllum, Valorisation
Published
2016

21. Renal lymphangiectasia, a rare case of perirenal infiltration

Author

Parazols, F, Fournier, L, Bouvier, N, Pelage, JP, Lobbedez, T, Hurault de Ligny, B, Service de Néphrologie-Dialyse-Transplantation rénale [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), and Service de Radiologie [CHU Caen]

Subjects
Lymphangiectasie rénale, RMI, Lymphangiomatose rénale, Renal lymphangiomatosis, [SDV]Life Sciences [q-bio], Perirenal cysts, urologic and male genital diseases, Renal lymphangiectasia, IRM, Kystes périrénaux
Abstract

International audience; Renal lymphangiectasia is a bilateral cystic infiltration of the perirenal and parapelvic space which is caused by the obstruction of the renal lymphatic tissue. To our knowledge only numbers have been reported in the literature. Renal lymphangiectasia usually asymptomatic and incidentally diagnosed has absolutely no effect on the patient outcome. Radiological imaging is typical so that the diagnosis does not need to be confirmed by a cyst punction. The lack of knowledge concerning renal lymphangiectasia make it usually confused with another cause of polycystic renal infiltration, such as the polycystic kidney disease. We report herein a case of renal lymphangiectasia diagnosed incidentally by an abdominal ultrasonography.

Published
2015
Full Text
View/download PDF

22. Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, first-line 5FU/platinum and PD1/CTLA4 blockade

Author

Janjigian, Y.Y., primary, Sanchez-Vega, F., additional, Jonsson, P., additional, Tuvy, Y., additional, Bouvier, N., additional, Riches, J., additional, Kundra, R., additional, Ku, G., additional, Hechtman, J.F., additional, Kelsen, D., additional, Tang, L., additional, Ilson, D., additional, Vakiani, E., additional, Stadler, Z., additional, Callahan, M., additional, Solit, D.B., additional, Berger, M.F., additional, Taylor, B.S., additional, and Schultz, N., additional

Published
2016
Full Text
View/download PDF

24. Abstract P3-07-41: Genomic alterations indicative of a luminal A subtype associate with clinical benefit to buparlisib and letrozole in endocrine-resistant ER+/HER2– metastatic breast cancer

Author

Balko, JM, primary, Hicks, M, additional, Berger, MF, additional, Solit, DB, additional, Bouvier, N, additional, Sanders, ME, additional, Estrada, MV, additional, Won, H, additional, Cantley, LC, additional, Mayer, IA, additional, and Arteaga, CL, additional

Published
2016
Full Text
View/download PDF

25. Quantitative determination of varietal disulfides in wine and their behavior during alcoholic fermentation

Author

Bencomo-Rodriguez, J.J, Gambetta, J., Rigou, P., Canelo, N., Roland, Aurélie, Salmon, J.-M., Bouvier, N, Pharmacochimie des substances naturelles et pharmacophores redox, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Nyseos, Sciences Pour l'Oenologie (SPO), Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Recherche Agronomique (INRA), Université Montpellier 1 (UM1)-Institut de Recherche pour le Développement (IRD [Nouvelle-Calédonie])-Institut National de la Recherche Agronomique (INRA)-Université de Montpellier (UM)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut National de la Recherche Agronomique (INRA)-Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut de Recherche pour le Développement (IRD [Nouvelle-Calédonie])-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), and Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)

Subjects
disulfides, oxidation, Varietal thiols, [CHIM.ANAL]Chemical Sciences/Analytical chemistry, [SDV.IDA]Life Sciences [q-bio]/Food engineering, wine, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2011

31. 612O - Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, first-line 5FU/platinum and PD1/CTLA4 blockade

Author

Janjigian, Y.Y., Sanchez-Vega, F., Jonsson, P., Tuvy, Y., Bouvier, N., Riches, J., Kundra, R., Ku, G., Hechtman, J.F., Kelsen, D., Tang, L., Ilson, D., Vakiani, E., Stadler, Z., Callahan, M., Solit, D.B., Berger, M.F., Taylor, B.S., and Schultz, N.

Published
2016
Full Text
View/download PDF

33. Place de l’éculizumab lors de récidives après transplantation rénale d’un syndrome hémolytique et urémique atypique lié à une mutation familiale du gène du C3

Author

Crochette, R., primary, Hurault de Ligny, B., additional, Lobbedez, T., additional, Henri, P., additional, Ficheux, M., additional, Castrale, C., additional, Bouvier, N., additional, Ryckelynck, J.-P., additional, Frémaux-Bacchi, V., additional, and Chatelet, V., additional

Published
2013
Full Text
View/download PDF

37. Greffe rénale chez les patients dont la néphropathie initiale est une amylose AA : étude rétrospective multicentrique française portant sur 59 patients

Author

Kofman, T., primary, Grimbert, P., additional, Zuber, J., additional, Garrigue, V., additional, Mousson, C., additional, Frimat, L., additional, Kamar, N., additional, Couvrat, G., additional, Bouvier, N., additional, Pouteil-Noble, C., additional, Lang, P., additional, and Audard, V., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results